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Abstract
Background: We report a case of peripheral pigmentary retinopathy and visual field loss following topiramate use
for uncontrolled seizures. Such side effects have not been well documented despite the increasing use of
topiramate in the past 10 years. A thorough search of available English literature revealed only a small number of
reports of topiramate-induced retinopathy or visual field defects in humans. One similar case has been described.
We are concerned about the possible rare instances of this occurrence in future patients and hence would like to
propose a presumed correlation.
Case presentation: A 48-year-old Chinese woman developed blurred vision after 9 months of topiramate use. Her
visual acuity dropped from 1.2 to 0.7 in both eyes, with bilateral diffuse pigmentary retinopathy and a constricted
visual field. Despite an improvement in visual acuity after cessation of the drug, the other clinical findings remained.
The temporal relationship between the initiation of topiramate and the visual disturbance suggests that topiramate
could be the cause of such signs and symptoms.
Conclusion: Topiramate potentially causes pigmentary retinopathy and constricted visual field.
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Background
Topiramate is a sulfurated drug approved by the US
Food and Drug Administration (FDA) for the treatment
of partial seizures, migraine, depression, and neuropathic
pain. The off-label use of topiramate as a weight-
reducing agent has gained popularity. The common dos-
age used is in the range of 50 to 400 mg per day. Several
ocular side effects with explainable mechanisms have
been described by the World Health Organization [1],
including acute myopia, diplopia, and shallow anterior
chamber with angle closure. Other severe ocular side ef-
fects were mentioned in previous case reports but the
mechanism is not well understood [2]. We report a case
of presumed correlation between topiramate and bilat-
eral diffuse pigmentary retinopathy with visual field loss
9 months after initiation of topiramate therapy.
Case presentation
A 48-year-old Chinese woman with a history of a right
parasagittal meningioma with surgery and gamma knife
excision done, was first put on valproate but then
stepped up to topiramate 26 months later for uncon-
trolled seizures. The initial dose was topiramate 25 mg
twice a day, which was eventually stepped up to 100 mg
twice a day for adequate seizure control. She was re-
ferred to our ophthalmology clinic for dry eyes before
the use of topiramate, with an examination showing a
baseline visual acuity of 1.2 in both eyes with unremark-
able anterior segment and fundoscopy examination.
There was no family history of retinal diseases.
She complained of blurring of vision in both eyes after
using topiramate for 9 months. She was not on other
medications when her visual symptoms developed. On
examination, her visual acuity was 0.7 in both eyes. Her
pupils were equal with no relative afferent papillary defect.
The intraocular pressure, Ishihara test, and anterior seg-
ment examination were within normal limits. A fundus
examination revealed there was bilateral diffuse pigmentary
retinopathy (Fig. 1). Automated perimetry showed bilateral
peripheral constrictions (Fig. 2) while microperimetry
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showed normal macula sensitivity (Fig. 3). Autofluores-
cence fundus pictures showed loss of autofluorescence at
the periphery, which is compatible with areas of pigmentary
retinopathy (Fig. 4). A fundus fluorescein angiogram also
showed blocked fluorescence in the areas of pigmentation
(Fig. 5). Optical coherence tomography was unremarkable.
A full field electroretinogram (ERG) according to Inter-
national Society for Clinical Electrophysiology of Vision
(ISCEV) standard was performed at 16 months after onset
of symptoms (25 months since topiramate was first given).
Both photopic and scotopic responses were found to be
within normal limits. Administration of topiramate was im-
mediately ceased due to suspected correlation with her eye
signs and symptoms. She was switched to levetiracetam
monotherapy. There was no more seizure recurrence after
this treatment change.
All investigations were repeated 1 year after discon-
tinuation of topiramate. Bilateral diffuse pigmentary ret-
inopathy was still present, with visual field test showing
similar peripheral constriction, although her visual acu-
ity improved back to 1.0 in both eyes and she reported
subjective improvement in vision.
Discussion
It has been documented that topiramate can cause cilio-
choroidal effusion syndrome, leading to acute myopia,
acute angle closure, and macular striae [3]. However, a
thorough search of available English literature revealed
only a small number of reports of topiramate-induced
retinopathy or visual field defects in humans. One simi-
lar case has been described [4, 5].
The main visual abnormality found in our patient was
bilateral diffuse pigmentary retinopathy and constricted
visual field. Without family history of retinal disease,
and as our patient was only on topiramate monotherapy
while visual blurring occurred, no other risk factors for
developing such retinopathy could be identified other
than topiramate drug use. We cannot entirely exclude
the possibility that the retinal pathology was related to
the previous treatment with valproate; however, valpro-
ate is a commonly used antiepileptic and no such dis-
eases have been documented in literature. The time
course of development of visual impairment after
9 months’ use of topiramate, and the improvement of
our patient’s visual acuity after discontinuation of the
Fig. 1 Fundus photo showing bilateral diffuse pigmentary retinopathy
Fig. 2 Visual field Full-Field 120 test showing bilateral peripheral constriction
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drug suggests that topiramate is the top etiological fac-
tor. Hence, we presume her pigmentary retinopathy with
the constricted visual field was caused by topiramate
drug toxicity. However, as all structural and functional
macular parameters were normal, the reason why there
was a visual acuity drop remained unclear. A possible
explanation could be that the pigmentary retinopathy
was noted and topiramate was immediately stopped at
an early stage, when definite signs of maculopathy could
not be demonstrated yet.
A proposed mechanism of how topiramate leads to re-
duction in retinal function has been demonstrated in a
Fig. 3 Microperimetry showing normal macula sensitivity
Fig. 4 Fundus autofluorescence photos showing bilateral peripheral loss of autofluorescence, compatible with areas with peripheral pigmentary
retinopathy
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rabbit study [6]. Histopathological analyses found exten-
sive accumulation of gamma-aminobutyric acid (GABA)
in the inner retina, and ERG found reduction in 30 Hz
flicker b-wave amplitude. No human studies have been
done so far hence the actual mechanism remains uncertain.
Topiramate is an antiepileptic drug that works on
multiple mechanisms, including enhancement of GABA
receptor activity. Vigabatrin is another GABAergic anti-
epileptic drug that is known to cause irreversible visual
field defects in more than 30 % of patients [7]. Hence, it
is reasonable to postulate that topiramate can cause ret-
inal toxicity similar to that caused by vigabatrin. Further
investigation is required before the suspected correlation
can be confirmed.
Conclusions
Topirmate potentially causes pigmented retinopathy and
constricted visual field. Although visual acuity returned to
normal after immediate cessation of the drug after visual
abnormality occurred, ophthalmological findings did not
show significant improvement. Hence it is difficult to
comment whether or not such pathologies are reversible
after discontinuation of drug. Whether the retinop-
athy is dose-related, whether there is any correlation
with duration of treatment, the risk factors for develop-
ing such retinopathy, and whether routine screening is
necessary, would rely on future studies to answer the
above questions.
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Fig. 5 Fundus fluorescein angiogram showing blocked fluorescence in the areas of pigmentation
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